PHARMACY

Report: More than a quarter of U.S. kids take at least one chronic med

BY Drug Store News Report

NEW YORK — More than 25% of children and teens take at least one medication on a daily basis, and nearly 7% are on two or more drugs, the Wall Street Journal reported Tuesday, citing 2009 data from Medco Health Solutions. Drawing additional data from IMS Health, the article noted that prescriptions for hypertension in people under the age of 20 years could reach 5.5 million for 2010 by the time year-end results are tabulated, which would mark a rise of 17% since 2007. 

The rise in prescription drug use among children has been attributed to increasing awareness among physicians and parents of available therapeutic options for kids and teens, earlier screening and diagnosis of chronic disease, and a rise in unhealthy eating and exercise habits among kids. That has many healthcare professionals concerned. While much is known about the effects of drugs to treat such conditions as asthma and attention-deficit hyperactivity disorder, much less is known about the long-term effects of many other chronic care drugs on children — these drugs have been tested on adults, not kids, many experts have warned.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Bartell donates flu vaccines to help community outreach programs through local schools of pharmacy

BY Drug Store News Report

SEATTLE — In an effort to help people in local underserved communities and students in need stay well this flu season, Bartell Drugs will give 4,000 flu vaccines to the University of Washington and Washington State University for use in pharmacy programs at both universities. Each school will receive 2,000 doses of the current flu vaccines to support local student pharmacy outreach programs.

"We’re proud to give the donations to both schools in support of their missions of teaching and community service," said Bartell Drugs chairman and CEO George Bartell. "We’ve been an advocate of the programs at both schools for many years. This is a way for us to show our support for their ongoing outreach efforts to the communities they serve.”

UW’s School of Pharmacy will use the donated vaccines to benefit several local tribal communities and safety-net nonprofit organizations, including Aloha House, the Salvation Army and area drug treatment centers.

WSU’s College of Pharmacy will use its vaccines to boost immunization rates among college students in Pullman and Spokane — a group that is known to be traditionally under-vaccinated and particularly vulnerable to influenza infection due to high-density living conditions, which help foster the spread of the illness.


keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Cephalon appoints new CEO

BY Michael Johnsen

FRAZER, Pa. — Cephalon on Thursday appointed Kevin Buchi as CEO and a member of the company’s board.

The board will address the role of company chairman in the future, Cephalon stated in a press release. William Egan will continue to serve as Cephalon’s independent presiding director.

"Kevin is an experienced pharmaceutical executive who has been involved in every aspect of running our business," Egan stated. "Over the course of many years, Kevin worked closely with Frank Baldino Jr. to create the company that we know today, and he has the passion, leadership skills, organizational abilities and unwavering commitment to patients that are critical to ensuring Cephalon’s continued growth and success." 

Buchi, who has been with Cephalon for almost 20 years, had assumed day-to-day chief executive responsibilities for the company in August 2010. He previously served as a member of the Cephalon executive management team in the roles of COO and CFO. Additionally, for the last seven years, he has led the business development function with responsibility for mergers, acquisitions and in-licensing of products.

"Cephalon is an extraordinary company with one of the most robust pipelines in the industry focused on patients suffering from rare disorders and diseases for which there are no cures,” Buchi said. “We have expanded our global footprint dramatically in the last few years. I am confident that our diverse product portfolio, rich pipeline and global presence position us well for long-term growth and success."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?